Biomarker Twitter Feed

See what's happening across the Internet in biomarker development.


View on Twitter!

Prevention of Organ Failure Centre of Excellence

The PROOF (Prevention of Organ Failure) Centre is a not-for-profit organization that develops and implements blood-based biomarker tests to better manage patients with heart, lung and kidney failure and prevent disease progression. By embracing a cross-disciplinary team of people and uniting organizations including commercial partners, we can speed up the development of these tests, applying them sooner to improve and save lives.

Published work on assay well-suited for CVD biomarker validation

May 14, 2012

Congratulations to PROOF Centre team member Dr. Gabriela Cohen-Freue and PROOF Centre collaborator Dr. Christoph Borchers on their published work on…

Dr. Heesun Shin wins poster award at Bio-IT Conference and Expo

May 7, 2012

On April 24-26th, the 10th annual Bio-IT World Conference and Expo was held at the World Trade Center in Boston,…

What does being a leader mean to Dr. Bruce McManus?

May 4, 2012

Dr. Bruce McManus, Director of the PROOF Centre, is the proud recipient of the 2012 Milton Wong Award for Leadership.…

Why do we need biomarkers for COPD? Dr. Don Sin explains on Global BC

April 20, 2012

What is COPD and why do we need biomarkers to predict lung attacks? Click here to watch Dr.…

More News

February 5-7, 2012

AllerGen Seventh Annual Research Conference: Innovation from Cell to Society Fairmont Royal York, Toronto, Ontario Dr. Scott Tebbutt, Chief Scientific…

November 30, 2011

Personalized Healthcare – a Sustainability Solution? The capacity to make care more particular and specific to each person…

November 30, 2011

Applications for Affymetrix® Microarrays 12:00pm to 2:00pm, UBC James Hogg Research Centre at St. Paul’s Hospital, Vancouver, BC.…

More Events

Why work with us?

As a not-for-profit organization, we can provide flexible partnering opportunities.
We can provide multiple potential points of collaboration with a focus on critical clinical needs and opportunities through strategic engagement of industry, academia, government, and clinician stakeholders.
We have an agnostic approach to technology platforms, allowing multiple and best in class choices.

We provide single-point access to cohorts, technology platforms and renowned experts in all facets of heart, lung and kidney failure.